Aptevo Therapeutics (NASDAQ:APVO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research note issued to investors on Sunday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Roth Mkm lowered their price target on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a report on Monday, September 23rd.

Aptevo Therapeutics Price Performance

Shares of NASDAQ APVO opened at $0.24 on Friday. The business’s 50 day moving average is $0.23 and its two-hundred day moving average is $0.38. Aptevo Therapeutics has a 1-year low of $0.14 and a 1-year high of $10.80.

Institutional Investors Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent quarter. Institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.